Gesundheitsoekonomie und Qualitaetsmanagement, published by THIEME MEDICAL PUBL INC, serves as a vital resource in the field of health policy, particularly within the context of Germany. Since its inception in 1999, this journal has been committed to advancing the discourse on health economics and quality management, making significant contributions to understanding the complexities of healthcare systems. With an impact factor that reflects its ongoing importance, the journal is categorized in the Q4 quartile for Health Policy as of 2023, indicating its role in serving a niche yet crucial space in medical literature. Although currently not an open access journal, it remains accessible through various academic platforms, making its content available to a diverse audience of researchers, healthcare professionals, and students eager to engage with contemporary issues in health economics. With its publication continuing through 2024, Gesundheitsoekonomie und Qualitaetsmanagement is essential for anyone looking to deepen their understanding of the economic aspects of healthcare and ensure quality management in health services.

Drugs-Real World Outcomes, published by SPRINGERNATURE, is an influential open access journal dedicated to the dissemination of research concerning the real-world impact of pharmacological therapies. Since its inception in 2014, this journal has established a significant presence in the field of Pharmacology, evidenced by its classification in the Q2 quartile for 2023 and a Scopus rank of #141 out of 272 in the medical pharmacology category, placing it in the 48th percentile. The journal’s scope encompasses a diverse range of studies aimed at bridging the gap between clinical research and practical outcomes, making it an essential resource for researchers, healthcare professionals, and students alike. Located in Switzerland, Drugs-Real World Outcomes allows researchers unfettered access to vital data, enhancing knowledge translation and improving health care practices. As it continues to evolve, the journal remains committed to fostering high-quality research that informs and advances the field of pharmacological therapies.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

The Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.

Expert Opinion on Orphan Drugs is a pivotal academic journal published by Taylor & Francis Ltd, focusing on the burgeoning field of orphan drugs, which are often essential for treating rare diseases. As an integral source of insights and advancements from 2013 to 2024, this journal aims to bridge the gap between emerging scientific research and clinical application, providing a platform for authors to discuss pharmacological innovations and policy implications. With its ISSN 2167-8707, the journal has established a reputably rigorous editorial process and is indexed in Scopus, showcasing its relevance with ranks in various pharmacology and health policy disciplines. Though currently not an open-access journal, it endeavors to deliver high-quality articles that are vital for researchers, healthcare professionals, and policy makers aiming to navigate the complexities and challenges in the orphan drug landscape. It is categorized in Q4 for Health Policy and Q3 for Pharmacology in recent evaluations, reflecting its accessible yet scholarly contributions to this niche area of medical research.

ClinicoEconomics and Outcomes Research is a prestigious open-access journal published by DOVE MEDICAL PRESS LTD, located in New Zealand. Since its inception in 2009, it has established itself as a vital resource for researchers and practitioners in the fields of economics, health policy, and outcomes research. With a commendable impact reflected in its rankings—Q1 in Economics, Econometrics and Finance and Q2 in Health Policy—the journal effectively bridges the gap between economic evaluation and healthcare delivery. This publication is particularly significant for those focused on the economic implications of health interventions, policy analysis, and decision-making processes in healthcare systems. As an open-access journal, ClinicoEconomics and Outcomes Research ensures that its valuable content is widely accessible, enhancing knowledge dissemination and fostering collaboration among academia, industry, and policymakers. With an ambition to contribute to the improvement of health outcomes through rigorous research, it invites submissions that address the multifaceted challenges facing the economics of healthcare today. Join the scholarly dialogue where innovative ideas in health economics thrive!

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE is a leading academic journal published by Cambridge University Press, specializing in the critical evaluation of healthcare technologies and their impact on health policy. Established in 1970, it has gained recognition within the field, currently holding a prestigious Q2 ranking in Health Policy, with a commendable position of #89 out of 310 in the Scopus rankings, placing it in the 71st percentile. The journal serves as an essential platform for researchers, professionals, and students interested in the intersection of technology and health care, facilitating the dissemination of innovative research findings and practical assessments that inform policy-making and improve health outcomes. With a focus on advancing knowledge from 1985 to 2024, the journal's content remains relevant and impactful. Though not open access, it offers subscription-based access to a wealth of articles that contribute to shaping the future of healthcare technology assessment.

Global & Regional Health Technology Assessment (ISSN: 2284-2403; E-ISSN: 2283-5733) is an esteemed open-access journal published by ABOUTSCIENCE SRL, dedicated to the dissemination of research in the field of health technology assessment on a global and regional scale. Since its inception in 2014, this journal has focused on the critical evaluation of health technologies, providing invaluable insights into their efficacy, cost-effectiveness, and impact on healthcare systems. With an increasing emphasis on public health and policy implications, the journal encourages interdisciplinary research that bridges gaps between technological innovations and health outcomes. Despite its relatively recent establishment, it has made significant inroads with Scopus rankings reflecting the growing importance of health technology assessment in global health discourse. The journal welcomes contributions from researchers, professionals, and students, inviting them to engage in discussions that shape the future of health technology, with the aim of informing stakeholders and policymakers worldwide.